RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi (R) has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of ...

U.S. health authorities have widened the approval of a closely debated medication designed to increase female libido, allowing the once-daily pill to be used by women over the age of 65. The decision, ...

On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women under the age of 65. Addyi was previously approved ...

Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...

Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.

Addyi, the first and only FDA-approved pill clinically proven to treat frustrating low sexual desire in women, is now approved for use in women who have gone through menopause RALEIGH, N.C., Dec. 15, ...

(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...

Please provide your email address to receive an email when new articles are posted on . Hypoactive sexual desire disorder is lack of motivation, desire, response or inability to keep interest in sex.

Share on Pinterest The FDA has expanded its approval of a libido-boosting drug to postmenopausal women. Xvision/Getty Images On December 15, 2025, the U.S. FDA approved Addyi (flibanserin) for the ...